Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Suraksha Diagnostic Ltd (SURAKSHA) is currently trading at 264.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Suraksha Diagnostic Limited operates an organized network of diagnostic centres across Eastern India offering integrated pathology, advanced radiology, genomics, and omnichannel medical consultations; the company runs multi-modality labs, 120 polyclinic chambers, and a broad test menu spanning routine pathology to advanced molecular and imaging services from a regional hub-and-spoke model. Q3 FY'26 showed strong top-line momentum with revenue of INR783.09 million (up 30.3% YoY) driven by center additions and product mix shifts toward genomics; tests performed rose 30.7% YoY to 2.06 million while patients increased 23% YoY, indicating both volume-led growth and early traction for higher-value molecular services. The company is pivoting to genomics as a strategic moat: Suraksha has launched a CAP-validated end-to-end genomics lab, recruited internationally recognized experts, is developing an HRD assay for ovarian cancer, and reported early genomics run-rates with management targeting a multi-fold scale-up by FY'27–FY'28 to materially alter margin and revenue composition. Expansion is capital‑intensive but controlled: management targets 12–15 new centres per year with annual capex near INR70 crore, expects margins to compress short-term because of pre‑operative costs on new centres but foresees margin recovery as new sites mature, and is targeting 100 centres by FY'28 to build scale and efficiencies. Financial health shows net cash positive position (management cites net cash around INR29 crore) despite ongoing rollout; Q3 EBITDA was INR237.82 million (30.6% margin) and PAT INR72.41 million, reflecting profitable operations at mature sites while overall margins are temporarily diluted by recent centre additions.
Over the past 52 weeks, Suraksha Diagnostic Ltd has traded between a low of ₹227.95 and a high of ₹353.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Suraksha Diagnostic Ltd has a market capitalization of approximately 1,383.79. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Suraksha Diagnostic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.25 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,383.79 Cr, Suraksha Diagnostic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Suraksha Diagnostic Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Suraksha Diagnostic Ltd is 42.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
4
Neutral
3
Bullish
7
Bearish
36
Neutral
3
Bullish
7
Bearish
32
Neutral
0
Bullish
0
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
609.60 | 1,951 Cr | 24.97 | 2.11 | 0.46 | 9.16 | 11.09 | 5.34 | |
428.00 | 1,918 Cr | 31.55 | 5.60 | 0.23 | 14.59 | 19.04 | 13.94 | |
270.00 | 1,384 Cr | 42.25 | 6.01 | 0.00 | 13.86 | 14.74 | 8.53 | |
595.05 | 1,163 Cr | 23.72 | 11.48 | 0.00 | 43.51 | 58.07 | 27.58 | |
258.80 | 633 Cr | 24.01 | 4.58 | 0.00 | 18.69 | 20.84 | 10.52 | |
319.00 | 372 Cr | 45.06 | 2.68 | 0.00 | 0.00 | 0.00 | 2.06 | |
75.40 | 114 Cr | 9.25 | 1.98 | 0.00 | 43.27 | 33.60 | 13.89 |
Suraksha Diagnostic Limited operates an organized network of diagnostic centres across Eastern India offering integrated pathology, advanced radiology, genomics, and omnichannel medical consultations; the company runs multi-modality labs, 120 polyclinic chambers, and a broad test menu spanning routine pathology to advanced molecular and imaging services from a regional hub-and-spoke model.
Q3 FY'26 showed strong top-line momentum with revenue of INR783.09 million (up 30.3% YoY) driven by center additions and product mix shifts toward genomics; tests performed rose 30.7% YoY to 2.06 million while patients increased 23% YoY, indicating both volume-led growth and early traction for higher-value molecular services.
The company is pivoting to genomics as a strategic moat: Suraksha has launched a CAP-validated end-to-end genomics lab, recruited internationally recognized experts, is developing an HRD assay for ovarian cancer, and reported early genomics run-rates with management targeting a multi-fold scale-up by FY'27–FY'28 to materially alter margin and revenue composition.
Expansion is capital‑intensive but controlled: management targets 12–15 new centres per year with annual capex near INR70 crore, expects margins to compress short-term because of pre‑operative costs on new centres but foresees margin recovery as new sites mature, and is targeting 100 centres by FY'28 to build scale and efficiencies.
Financial health shows net cash positive position (management cites net cash around INR29 crore) despite ongoing rollout; Q3 EBITDA was INR237.82 million (30.6% margin) and PAT INR72.41 million, reflecting profitable operations at mature sites while overall margins are temporarily diluted by recent centre additions.
Healthcare
Diagnostic Services
1,384 Cr
Low Risk
42.3
42.1
2.1
6.0
353.65
227.95
Sales CAGR
Profit CAGR
ROE
ROCE
